Shionogi inks deal with MPP for production of COVID-19 oral antiviral ensitrelvir generics
Japanese pharma major Shionogi (TYO: 4507) has signed seven sublicence agreements with the Medicines Patent Pool (MPP), a United Nations-backed international public health organization, for generic version of Shionogi's ensitrelvir fumaric acid, a COVID antiviral, to be manufactured by generics companies.
The collaboration aims to increase access to life-saving medicines for low- and middle-income countries (LMICs).
The announcement was made on the sidelines of a business briefing in Tokyo co-convened by MPP and global health partnership Unitaid. The sublicence agreements were signed with three generic manufacturing companies from China: Zhejiang Charioteer Pharmaceutical, Zhejiang Lepu Pharmaceutical and Fosun International; two from India: Hetero and Laurus Labs; and with Ukrainian company Joint Stock Company Lekhim and Vietnamese company Stellapharm.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Generics
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze